Photocure ASA · OSL:PHO
Photocure ASA — DNB Virtual Healthcare Conference 2020
18 slides from Photocure ASA's conference presentation, Dec 15, 2020
Slide 1: Photocure ASA – DNB Virtual Healthcare Conference 2020
Photocure ASA DNB Virtual Healthcare Conference 2020 15 December 2020 Daniel Schneider, President and CEO Erik Dahl, CFO
Slide 2: Disclaimer
Disclaimer By reading this company presentation (the “Presentation”) or attending any meeting or oral presentation held in relation thereto, you (the “Recipient”) agree to be bound by the following terms, conditions and limitations. The Presentation has been produced by Photocure (the “Company”) for
Slide 3: Global commercial-stage bladder cancer specialist headquartered in Oslo
Global commercial-stage bladder cancer specialist headquartered in Oslo Direct sales in U.S. & Europe with worldwide partnerships Approved for NOK use in 281.6M ~30 total company countries revenue 2019 Symbol: PHO (OSE) ~100 >500K Market Cap*: NOK 2,268M employees patients Shares Outstanding: 26.3M
Slide 4: Bladder cancer has been chronically underserved
Bladder cancer has been chronically underserved COMMON (6th most common cancer worldwide1) EXPENSIVE Highest USD 550K 200K per patient new cases annually1 deaths annually of which 75% lifetime treatment costs of any 5.7B Cost of Bladder Cancer in the U.S., projection are men1 cancer2 for 20203 RECUR
Slide 5: Blue Light Cystoscopy: Creating a New Standard of Care
Blue Light Cystoscopy: Creating a New Standard of Care “You cannot treat what you cannot see!” Improved detection vs. white light cystoscopy alone1–4 Hexvix®/Cysview® is a drug that preferentially accumulates in bladder cancer cells, making them glow bright pink during blue light cystoscopy5 Hexvix
Slide 6: The Patient Journey: Characterized by long term follow-up with repeat procedures
The Patient Journey: Characterized by long term follow-up with repeat procedures NMIBC MIBC Urologist performs TURBT initial cystoscopy procedure, biopsy to Blood in the If suspected confirm Chemotherapy or urine or other bladder cancer diagnosis, BCG treatment symptom diagnosis, refer remove all ba
Slide 7: Increasing media attention for the BLC procedure and bladder cancer
Increasing media attention for the BLC® procedure and bladder cancer AUA News article Sept 2020 UroToday 11 and 24 June, 13 September 2020 Norwegian patient association magazine Sept 2020
Slide 8: Supportive environment for becoming the standard of care
Supportive environment for becoming the standard of care for the detection & management of bladder cancer Recommended in global & national guidelines: © Photocure - Confidential 8
Slide 9: Thousands of bladder cancer patients worldwide have benefited from our breakthrough product
Thousands of bladder cancer patients worldwide have benefited from our breakthrough product Leading positive change through: A single-minded focus on Ongoing collaborations The passion and commitment one therapy area and research of our people Commercial Organization Dedicated to Bladder Cancer Mana
Slide 10: U.S.: Continued blue light cystoscope placements despite challenges of pandemic
U.S.: Continued blue light cystoscope placements despite challenges of pandemic Annual New Installations Cumulative install base continues strong trend Tower placements by year 70 300 65 60 250 33 Surgical & Surveillance Approvals 50 54 Inclusion in Guidelines 26 220 200 New Commercial Team/Leadersh
Slide 11: Highlights in the 3rd quarter 2020
Highlights in the 3rd quarter 2020: +20% +14% European operations Partnership news: U.S. Revenue Growth Hexvix/Cysview Revenue Growth live on Cevira: 1st Phase 3 patient dosed in China (adjusted) 1 October 2 Genotests: Hexvix partnership in Chile Cash balance end of Q3 2020: NOK 322M 11
Slide 12: Signs of recovery in U.S. to prior growth trend
Signs of recovery in U.S. to prior growth trend Q3 resurges with 17% unit growth from Q3 2019 amidst Covid-19 3500 1400 3000 1200 2500 1000 YTD KITS BY QUARTER 2000 800 KITS 1500 600 1000 400 500 200 0 Q1 Q2 Q3 0 QUARTERS BY YEAR JAN FEB MAR APR MAY JUN JUL AUG SEP 2018 2019 2020 2018 2019 2020 12
Slide 13: Launching Hexvix Operations in Europe
Launching Hexvix® Operations in Europe Adds ~NOK 120M, or nearly 50% more revenue to Photocure’s revenue base in 2020 Key commercial resources in place and direct promotion initiated on 1 October 100% of previous Ipsen DACH Hexvix sales force now employed by Photocure ensuring no disruption in servi
Slide 14: Hexvix/Cysview – key market enablers in place: ready for growth
Hexvix®/Cysview® – key market enablers in place: ready for growth and our ambition to become the standard of care POSITION IN THE LIFE CYCLE KEY SUCCESS FACTORS Penetration 100% APPROVAL SURGICAL & SURVEILLANCE 75% ACCEPTANCE MAJOR & LOCAL GUIDELINES* 50% PERMANENT AND FAVORABLE Nordic ACCESS REIMBU
Slide 15: CEVIRA: Value From License of Non-Core Asset to Asieris
CEVIRA®: Value From License of Non-Core Asset to Asieris License Agreement terms: Asieris is a Chinese subsidiary focused on genito-urinary diseases, with their own product USD 250M potential in total: candidate in clinical development in China and the US for the treatment of NMIBC 1B USD 5M UP-FRON
Slide 16: Our Mission: Delivering transformative solutions to improve the lives of bladder cancer patients
Our Mission: Delivering transformative solutions to improve the lives of bladder cancer patients Photocure’s four step strategy will deliver our mission 4 3 Transform 2 Acquire Build a global Bladder Cancer Company 1 Expand Partner and in-license Build pipeline – partner/ acquisitions synergistic as
Slide 17: Investment Highlights
Investment Highlights Photocure has established a position as an innovation leader in the bladder cancer treatment market Our Hexvix®/Cysview® product is a best-in-class solution for the detection, staging, and long-term management of bladder cancer Treatment guidelines and reimbursement support our
Slide 18: Leading change in bladder cancer Q&A
Leading change in bladder cancer Q&A 18